Prognostic role of PD-L1 for HCC patients after potentially curative resection: a meta-analysis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1475-2867
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Prognostic role of PD-L1 for HCC patients after potentially curative resection: a meta-analysis ; volume:19 ; number:1 ; day:29 ; month:1 ; year:2019 ; pages:1-12 ; date:12.2019
Cancer cell international ; 19, Heft 1 (29.1.2019), 1-12, 12.2019
- Urheber
-
Liu, Gao-Min
Li, Xu-Gang
Zhang, Yao-Min
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12935-019-0738-9
- URN
-
urn:nbn:de:101:1-2019030323001463767183
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:59 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Liu, Gao-Min
- Li, Xu-Gang
- Zhang, Yao-Min
- SpringerLink (Online service)
Ähnliche Objekte (12)
Enhancing HCC Treatment: innovatively combining HDAC2 inhibitor with PD-1/PD-L1 inhibition
A new proposal for secondary surveillance following potentially curative therapy of HCC: alternating MRI and CEUS
PD-L1+ neutrophils induced NETs in malignant ascites is a potential biomarker in HCC
Correction to: A new proposal for secondary surveillance following potentially curative therapy of HCC: alternating MRI and CEUS
Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study
Thermal ablation—an option in curative treatment of HCC
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
PD-L1 Expression als Prognosemarker beim Endometriumkarzinom
Factors correlating the expression of PD-L1
Optimized PD-L1 scoring of gastric cancer
Urogenital Microbiota:Potentially Important Determinant of PD-L1 Expression in Male Patients with Non-muscle Invasive Bladder Cancer
Enhancing HCC Treatment: innovatively combining HDAC2 inhibitor with PD-1/PD-L1 inhibition
A new proposal for secondary surveillance following potentially curative therapy of HCC: alternating MRI and CEUS
PD-L1+ neutrophils induced NETs in malignant ascites is a potential biomarker in HCC
Correction to: A new proposal for secondary surveillance following potentially curative therapy of HCC: alternating MRI and CEUS
Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study
Thermal ablation—an option in curative treatment of HCC
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
PD-L1 Expression als Prognosemarker beim Endometriumkarzinom
Factors correlating the expression of PD-L1
Optimized PD-L1 scoring of gastric cancer
Urogenital Microbiota:Potentially Important Determinant of PD-L1 Expression in Male Patients with Non-muscle Invasive Bladder Cancer
Enhancing HCC Treatment: innovatively combining HDAC2 inhibitor with PD-1/PD-L1 inhibition
A new proposal for secondary surveillance following potentially curative therapy of HCC: alternating MRI and CEUS
PD-L1+ neutrophils induced NETs in malignant ascites is a potential biomarker in HCC
Correction to: A new proposal for secondary surveillance following potentially curative therapy of HCC: alternating MRI and CEUS
Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study
Thermal ablation—an option in curative treatment of HCC
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
PD-L1 Expression als Prognosemarker beim Endometriumkarzinom
Factors correlating the expression of PD-L1
Optimized PD-L1 scoring of gastric cancer